Table 2.
Breakdown of Data Stratification Factors of the 147 Evaluable Treatment Groups
| Treatment Modality | ||||||
|---|---|---|---|---|---|---|
| Anti-VEGF | Anti-VEGF + PDT | PDT | Othera | Total | ||
| Type of wAMD | Typical AMD | 20 | 1 | 3 | 1 | 25 |
| PCV | 40 | 23 | 19 | 3 | 85 | |
| Otherb | 24 | 2 | 5 | 6 | 37 | |
| Total | 84 | 26 | 27 | 10 | 147 | |
Notes: aIncludes treatment with steroids or pegaptanib. bDisease type that cannot be classified as typical AMD or PCV.
Abbreviations: AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; PDT, photodynamic therapy; VEGF, vascular endothelial growth factor; wAMD, wet AMD.